Role of serum adropin measurement in the assessment of insulin resistance in obesity

Basit Öğe Kaydı
dc.authorid0000-0001-5114-8660en_US
dc.contributor.authorErman, Hande
dc.contributor.authorÖzdemir, Ali
dc.contributor.authorSitar, Mustafa Erinç
dc.contributor.authorÇetin, Seher İrem
dc.contributor.authorBoyuk, Banu
dc.date.accessioned2024-07-12T21:04:44Z
dc.date.available2024-07-12T21:04:44Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractObesity has recently been mentioned as a metabolic pandemic in developed and developing countries and is an important known risk factor for type 2 diabetes and cardiovascular diseases. The main mechanism responsible for obesity is insulin resistance. Adropin is a peptide-structured regulatory hormone that is suggested to play a role in insulin resistance and metabolic regulation. We aimed to evaluate the associations of serum adropin with insulin resistance and clarify the factors affecting serum adropin concentrations. The study included 50 obese patients and 22 healthy controls. Patients with chronic disease and drug use history were excluded. Serum adropin and other metabolic parameters were obtained after overnight fasting. ELISA was used to measure serum adropin concentrations. The homeostatic model assessment-insulin resistance (HOMA-IR) index was used to calculate insulin resistance. Insulin resistance was defined as HOMA-IR >2.5. Serum adropin values were found to be low in the obese otherwise healthy patient group (p<0.001). Linear regression analysis revealed that age, body mass index (BMI), waist circumference (WC), high-density lipoprotein cholesterol, fasting glucose, and HOMA-IR affect serum adropin level. In multiple regression analysis, age is the most significant factor affecting serum adropin concentration. Serum adropin concentrations were negatively correlated with BMI, WC, diastolic blood pressure, fasting glucose, and insulin. Serum adropin concentrations were low in obese patients and the optimum cut-off point for adropin to indicate HOMA-IR at 2.5 is 216.7 ng/L. The findings suggest that serum adropin may contribute to the regulation of glycolipid metabolism and insulin resistance in obese patients.en_US
dc.identifier.citationErman, H., Özdemir, A., Sitar, M.E., Çetin, S.İ. ve Boyuk, B. (2021). Role of serum adropin measurement in the assessment of insulin resistance in obesity. Journal of Investigative Medicine, BMJ Journals. 69, s. 1318-1323.en_US
dc.identifier.doi10.1136/jim-2021-001796
dc.identifier.endpage1323en_US
dc.identifier.issn1708-8267
dc.identifier.pmid34016737en_US
dc.identifier.scopus2-s2.0-85106462515en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1318en_US
dc.identifier.urihttps://jim.bmj.com/content/69/7/1318
dc.identifier.urihttps://doi.prg/10.1136/jim-2021-001796
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3827
dc.identifier.volume69en_US
dc.identifier.wosWOS:000702445200009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSitar, Mustafa Erinç
dc.language.isoenen_US
dc.publisherBMJ Journalsen_US
dc.relation.ispartofJournal of Investigative Medicineen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY01942
dc.titleRole of serum adropin measurement in the assessment of insulin resistance in obesityen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu